AI revenue cycle management: what’s funding like now?

All funding deals in the AI revenue cycle management market over the last 24 months

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the AI revenue cycle management market.

Is the AI revenue cycle management market getting weaker?

The AI revenue cycle management (RCM) funding market is clearly weaker for startups trying to raise their first round, even though companies already backed by investors are still finding money.

Over the last 12 months, total funding fell 45%, from $685.5 million to $377 million. Deal count declined from 28 to 23, and the number of funded companies dropped from 26 to 22. Yet the median financing increased slightly, from $9.55 million to $10 million.

The biggest change came from first-time fundraising. Only four companies received their first financing, compared with nine in the previous period. Meanwhile, the number of follow-on rounds stayed exactly the same at 19.

The previous year also benefited from several unusually large investments, including Ambience Healthcare's $243 million Series C. Their disappearance explains much of the drop in total funding.

So the market has become harder for newcomers, while established startups still have access to capital. The problem is particularly visible at the beginning of the funding pipeline.

Funding metric	Last 12 months	Previous 12 months	Change
Total funding	$377.0M	$685.5M	−45.0%
Funding deals	23	28	−17.9%
Funded companies	22	26	−15.4%
Median round	$10.0M	$9.55M	+4.7%
Average round	$16.39M	$24.48M	−33.0%
First financings	4	9	−55.6%
Follow-on financings	19	19	Unchanged
Largest round	$120M	$243M	−50.6%

Did AI RCM funding really collapse, or did a few big deals disappear?

The apparent collapse in AI RCM funding is heavily influenced by unusually large rounds. Once we remove financings above $50 million, the decline shrinks from 45% to 19.7%.

The previous period included Ambience Healthcare's $243 million Series C, announced in July 2025, alongside two other rounds above $50 million. Those three deals represented 53.3% of all capital raised during the year.

By comparison, the latest 12-month period produced only one financing above $50 million: Candid Health's $120 million Series D.

Stedi complicates the comparison further. Its August 2025 announcement described a $70 million Series B package comprising $50 million in previously unannounced funding and $20 million in new capital. Our database records the full $70 million. Counting only the incremental $20 million would reduce previous-period funding by $50 million and make the headline decline approximately 40.7%, rather than 45%.

Even after excluding every round above $50 million, capital declined from approximately $320 million to $257 million. Underlying funding was therefore weaker, although nowhere near as dramatically as the headline suggests.

Funding concentration	Last 12 months	Previous 12 months
Total capital	$377.0M	$685.5M
Excluding rounds above $50M	$257.0M	$320.0M
Excluding rounds above $100M	$257.0M	$442.5M
Largest round	$120M	$243M
Largest deal's capital share	31.8%	35.4%
Top three deals' capital share	51.7%	53.3%
Top five deals' capital share	63.7%	64.6%
Number of rounds above $50M	1	3

Are fewer AI RCM startups getting funded now?

Yes. AI RCM investors financed 22 companies during the latest 12 months, compared with 26 previously. That's four fewer funded businesses in an already relatively small market.

The decrease was most visible in North America, where transactions fell from 27 to 18. The drop was partly offset by more activity in Europe and the appearance of financings in Latin America and Asia-Pacific.

There was at least one AI RCM deal in every monthly window during the latest period, whereas the previous period had one month without any transactions.

Activity remained fairly continuous, but median monthly invested capital fell from $20.14 million to $12.12 million. Fewer substantial checks were being written.

The smaller companies that managed to secure funding did not necessarily receive less money, either. The overall median round remained around $10 million, despite the sharp decline in total capital.

Are investors abandoning new AI RCM startups?

New AI RCM startups are having a much harder time attracting their first investment, and the reduction is considerably worse than the overall funding slowdown.

We counted just four first financings during the latest year, compared with nine previously. Combined funding for these initial rounds dropped from $39.45 million to $9.98 million, a 74.7% decrease.

Their median size also declined from $4 million to $2.6 million. Fewer new companies managed to raise money, and those that did generally received smaller initial checks.

This happened while Seed and Series A rounds continued representing most transactions. A startup can be classified as Seed or Series A without being a first-time recipient of venture capital, which helps explain the apparent contradiction.

Investors appear particularly cautious about adding new companies to their portfolios. The figures tell us less about the total number of startups being created, since companies that never seek or secure institutional financing are outside this analysis.

Are established AI RCM companies taking nearly all the money?

Previously funded AI RCM companies now account for 97.4% of invested capital, but even their average funding situation has deteriorated.

Follow-on rounds brought in $367 million during the latest period, compared with $646 million previously. Despite the decline in capital, the number of follow-on transactions remained unchanged at 19.

Their median size dropped from $21 million to $10 million. Investors continued backing familiar companies, but the typical follow-on financing became considerably smaller.

Candid Health was the obvious exception, securing $120 million after reporting strong commercial growth.

Within-period repeat fundraising was also less common. Only one company completed multiple financings during the latest 12 months, compared with two in the preceding year.

We cannot tell whether companies are taking longer to raise again because previous-round dates are not consistently available across the full sample. But the preference for companies with an existing funding history is unmistakable.

Financing measure	Last 12 months	Previous 12 months
First-financing deals	4	9
First-financing deal share	17.4%	32.1%
First-financing capital	$9.98M	$39.45M
First-financing capital share	2.6%	5.8%
Median first financing	$2.60M	$4.00M
Follow-on deals	19	19
Follow-on deal share	82.6%	67.9%
Follow-on capital	$367.02M	$646.03M
Follow-on capital share	97.4%	94.2%
Median follow-on round	$10.00M	$21.00M

Which AI revenue cycle management categories are attracting more investors?

Denial management and appeals have become the strongest funding growth category in AI RCM, with medical coding also attracting a larger share of deals.

Denial management funding increased from $11.2 million to $95.1 million. Its share of transactions climbed from 10.7% to 26.1%, while its median round jumped from $4 million to $16.5 million.

Medical coding AI followed a different path. The category increased its deal share from 17.9% to 26.1%, although total funding declined from $85.5 million to $70.2 million. The median round still increased from $8 million to $10 million.

Meanwhile, patient access and eligibility AI lost momentum. Deals dropped from eight to three, even though median financing increased from approximately $4.43 million to $8.5 million.

Claims submission and scrubbing also went from six financings to two. However, the segment attracted almost 32% of total capital because of Candid Health's $120 million investment.

Payment posting and reconciliation had a smaller improvement, with deals increasing from one to two and capital rising from $19 million to $41.5 million.

Denial management stands out because more transactions, more capital and larger median checks all moved in the same direction.

Why are investors suddenly interested in denial management AI?

Denial management AI has attracted far more funding because the technology targets one of healthcare providers' most expensive administrative problems: getting paid for services they've already delivered.

When an insurer denies a claim, a provider may need to identify missing documentation, correct coding errors, investigate eligibility or submit an appeal. Every additional step consumes staff time and delays reimbursement.

Sixth Street highlighted this problem when explaining its investment in Candid Health. The investor cited survey evidence that nearly three-quarters of providers were experiencing rising claim denials, while more than 40% reported denial rates above 10%.

Software that helps providers prevent denials, identify mistakes or recover reimbursement can potentially demonstrate financial returns without requiring customers to change their entire clinical operation.

Companies are also moving beyond isolated coding tasks toward broader revenue assurance. Arintra, for instance, raised a $25 million Series B in August 2026 to expand its AI-powered revenue assurance platform. The company had already announced that its 2025 revenue grew eightfold, alongside a fivefold increase in monthly coding volume.

The funding shift is clear, although the data cannot establish how much of it is attributable to rising denial rates.

Is medical coding AI losing momentum?

Medical coding AI is holding up better than its declining funding total suggests. Investors are financing a larger share of coding companies, and the median round has increased.

The category's capital fell from $85.5 million to $70.2 million, but its share of all AI RCM deals rose to 26.1%. That makes coding one of the two most frequently financed categories in the current sample, alongside denial management.

Arintra reported eightfold revenue growth for 2025 and said its autonomous coding platform handled more than five times as much monthly coding volume as the year before. Its February 2026 announcement also claimed that customers had reduced coding costs by nearly one-third.

Ambience Healthcare has been working on a broader version of the same problem. Its software connects clinical documentation, diagnosis coding and clinical documentation integrity directly to the care process. In 2025, the company announced additional integrations with Epic and reported deployments covering more than 100 medical specialties.

The boundaries of medical coding AI are changing. Some companies sell coding automation directly, while others embed coding into wider clinical and financial workflows.

Has AI RCM funding moved beyond the seed stage?

AI RCM funding is still overwhelmingly concentrated in Seed and Series A, and the latest figures show little evidence of a move toward later-stage financing.

Seed rounds accounted for approximately 39% of deals in both periods. Series A increased its share from 32.1% to 39.1%, although the actual number of Series A transactions stayed at nine.

Series B declined from three deals to one, while Series C went from two to one. One Series D+ financing appeared during the current period: Candid Health's $120 million round. Later-stage activity remained a relatively small part of the market.

We also calculated the approximate age of companies receiving funding. Median age increased only slightly, from 2.5 to three years. More surprisingly, the median age of follow-on recipients declined from four years to three.

The market remains focused on relatively young companies. The big difference is that fewer of those companies are securing their first financing.

Why did Candid Health manage to raise $120 million when everyone else was struggling?

Candid Health secured the largest AI RCM round of the year after reporting strong commercial growth and customer retention, making its $120 million financing an exception in a difficult market.

The Series D, announced in July 2026, was led by Sixth Street Growth, with participation from Oak HC/FT, 8VC and Y Combinator.

Candid reported 190% year-over-year growth in annual contracted run-rate revenue and 180% net dollar retention during 2025. It also said its valuation had tripled since its February 2025 Series C.

The company builds software that automates revenue cycle operations, including claims submission and billing workflows. Its approach combines a configurable rules engine with AI agents that handle tasks previously performed manually by billing teams.

Sixth Street explained that it was attracted to Candid's position inside essential healthcare workflows, its technical capabilities and its focus on measurable customer outcomes.

Candid had already raised a $52.5 million Series C in February 2025, making the latest round another major investment in a relatively short period.

Ambience Healthcare's previous-period $243 million financing offers a useful comparison. It too had evidence of adoption across major health systems. Large investors were already favoring companies with substantial customer deployments rather than treating AI capabilities alone as sufficient proof.

Are AI RCM investors becoming more selective?

AI RCM investors appear to have become more selective about financing new companies, while continuing to support businesses they already know.

We identified 20 distinct disclosed lead-investor names in the latest period, compared with 27 previously. However, disclosure coverage also declined, so this should not be interpreted as a precise reduction in the active investor population.

Strategic participation was almost unchanged. Four current-period deals explicitly involved strategic investors, compared with five previously, representing 17.4% and 17.9% of transactions.

Recent examples include health-system-associated investors backing Arintra, Ethermed and Joyful Health, alongside MTI's participation in Japan-based mutex.

Arintra's $25 million Series B included the Yale New Haven Health Center for Health Care Innovation and Endeavor Health Ventures. Endeavor Health had also participated in the company's earlier financing and adopted its technology.

That investor-customer overlap is particularly relevant in healthcare, where implementing software across clinical and financial systems can be a substantial undertaking.

Still, the stronger change is in who receives funding, rather than the composition of the investor base itself. Corporate participation remained fairly stable, while first-time financing became much rarer.

Is AI RCM funding spreading beyond the United States?

AI RCM financing has become more geographically diverse, although North America still receives the overwhelming majority of investment.

North America's deal share fell from 96.4% to 78.3%, while its capital share declined from 99.5% to 91.8%.

Europe increased from one financing to two, with capital rising from $3.5 million to $21.4 million. Latin America appeared with two deals totaling $9 million, and Asia-Pacific recorded one $400,000 financing.

These amounts are still small compared with North America's $346.2 million in funding during the latest period.

The geographic expansion is more significant in the number of regions represented than in the distribution of money. U.S. reimbursement workflows remain central to many of the best-funded AI RCM businesses, including Candid Health, Ambience Healthcare and Arintra.

Geography	Current deals	Previous deals	Current capital	Previous capital
North America	18	27	$346.2M	$682.0M
Europe	2	1	$21.4M	$3.5M
Latin America	2	0	$9.0M	$0
Asia-Pacific	1	0	$0.4M	$0
Total	23	28	$377.0M	$685.5M

Do AI RCM startups need more traction to raise money now?

AI RCM startups with strong commercial traction can still attract very large rounds, but we cannot establish that investors have raised their requirements across the entire market.

Candid Health's $120 million financing is the clearest recent example, backed by reported revenue growth, strong customer retention and an increasing valuation.

Arintra offers another example at a smaller scale. Its August 2026 Series B followed a period of strong reported revenue growth, increasing coding volumes and broader adoption by health systems.

Ambience Healthcare was already demonstrating substantial deployment activity before its July 2025 financing. Cleveland Clinic announced a rollout of its platform in February 2025, while John Muir Health had reported enterprise adoption across multiple specialties.

These businesses had customers using their products at scale, but the evidence does not show that investors have become more demanding than they were a year earlier.

Company age offers little confirmation of such a shift. The median age of funded businesses increased by roughly six months, too modest a change to establish a meaningful difference in investment criteria.

The clearer finding is that fewer companies are receiving their first financing. Among the businesses securing the largest rounds, commercial adoption was already important in the previous period.

Are AI RCM companies raising money to build products or expand their businesses?

The largest AI RCM financings are increasingly associated with expanding commercial platforms, although product development remains an important part of how companies use the money.

Candid Health's July 2026 Series D was intended to scale its autonomous revenue cycle platform. The company's reported revenue growth suggests that expansion was a major priority.

Arintra's August 2026 Series B was similarly linked to growing its revenue assurance platform, expanding across health systems and developing automation capabilities throughout the revenue cycle.

Ambience Healthcare's $243 million Series C in the previous period had comparable ambitions. The company wanted to accelerate deployments across health systems while continuing to expand its clinical documentation and coding technology.

Enterprise deployment is a major part of the work. Winning a hospital or medical group is only the beginning; the software must also integrate with existing records, billing systems, coding requirements and staff workflows.

Ambience's deployment with Ardent Health and its integrations with Epic illustrate the scale of that effort.

However, the available deal records do not consistently divide proceeds into R&D, hiring, sales, acquisitions or international expansion. That prevents a reliable calculation of how the market's overall spending priorities have changed between the two years.

What really changed over the last 12 months?

AI RCM funding became noticeably harder for new startups. Only four companies raised an initial financing, compared with nine previously, and the total amount invested in those rounds fell nearly 75%. This is the sharpest deterioration in the market.

The headline funding decline overstates the broader contraction. Total capital dropped 45%, but the contraction falls to 19.7% after excluding rounds above $50 million. Last year's exceptional financings, particularly Ambience Healthcare's $243 million Series C, explain much of the difference.

Existing companies kept raising, although their checks became smaller. Follow-on activity remained at 19 deals, but median financing declined from $21 million to $10 million. Previously funded companies captured 97.4% of invested capital.

Denial management became the standout category. Funding for denial management and appeals increased from $11.2 million to $95.1 million. Medical coding also gained deal share, while patient access and eligibility attracted substantially fewer transactions.

The market is still early-stage and overwhelmingly North American. Seed and Series A represented more than three-quarters of current transactions, while North America attracted over 90% of capital. Financing appeared in more regions, but the money remains highly concentrated.

The AI RCM funding market has become more selective, particularly for companies seeking their first investment. Established businesses continue attracting capital, and certain categories are growing rapidly. The biggest concern is the shrinking pipeline of newly financed startups.